Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
As an industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Avacc 3 has significant advantages over existing whooping cough vaccines
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It affects up to 10 per cent of women of reproductive age around the world
Subscribe To Our Newsletter & Stay Updated
